These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 25326835)

  • 41. Treatment of type 2 diabetes mellitus and the incretin system.
    Whitehill D
    S D Med; 2007 May; 60(5):197, 199. PubMed ID: 17694940
    [No Abstract]   [Full Text] [Related]  

  • 42. First in class. Two new diabetes drugs.
    Koredella T
    Diabetes Forecast; 2005 Aug; 58(8):35-6. PubMed ID: 16124101
    [No Abstract]   [Full Text] [Related]  

  • 43. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
    Grunberger G
    J Diabetes; 2013 Sep; 5(3):241-53. PubMed ID: 23489968
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diabetes quiz. How much do you know about Byetta?
    Flannery L
    Diabetes Self Manag; 2007; 24(4):52, 54. PubMed ID: 17663084
    [No Abstract]   [Full Text] [Related]  

  • 45. Challenges and strategies for moving patients to injectable medications.
    Siminerio L
    Diabetes Educ; 2006; 32 Suppl 2():82S-90S. PubMed ID: 16554432
    [No Abstract]   [Full Text] [Related]  

  • 46. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
    Simó R; Hernández C
    Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
    [No Abstract]   [Full Text] [Related]  

  • 47. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
    Minze MG; Klein MS; Jernigan MJ; Wise SL; Frugé K
    Pharmacotherapy; 2013 Jun; 33(6):627-38. PubMed ID: 23553357
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exenatide and pramlintide: new therapies for diabetes.
    Want LL; Ratner R
    Int J Clin Pract; 2006 Dec; 60(12):1522-3. PubMed ID: 17109659
    [No Abstract]   [Full Text] [Related]  

  • 49. An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes.
    Painter NA; Morello CM; Singh RF; McBane SE
    J Am Board Fam Med; 2013; 26(2):203-10. PubMed ID: 23471935
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B
    Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. GLP-1 receptor agonist confer target organ protection in type 2 diabetes.
    Bonnet F
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S1-2S2. PubMed ID: 28431665
    [No Abstract]   [Full Text] [Related]  

  • 52. Long-term Efficacy and Safety of Exenatide Treatment.
    Chirapongsathorn S; Anthanont P
    Mayo Clin Proc; 2015 Sep; 90(9):1304. PubMed ID: 26355405
    [No Abstract]   [Full Text] [Related]  

  • 53. In reply--Long-term Efficacy and Safety of Exenatide Treatment.
    Wysham CH
    Mayo Clin Proc; 2015 Sep; 90(9):1304-5. PubMed ID: 26355404
    [No Abstract]   [Full Text] [Related]  

  • 54. Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?
    Pratley RE
    Diabetes Technol Ther; 2016 Nov; 18(11):671-673. PubMed ID: 27860501
    [No Abstract]   [Full Text] [Related]  

  • 55. The Triumph of Innovation and the Hard Work of Caring for Patients With Diabetes.
    Montori VM; Rodriguez-Gutierrez R
    Ann Intern Med; 2016 Jan; 164(2):127-8. PubMed ID: 26641027
    [No Abstract]   [Full Text] [Related]  

  • 56. Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors).
    Nunez DJ; D'Alessio D
    Diabetes Obes Metab; 2018 Feb; 20(2):233-237. PubMed ID: 28842950
    [No Abstract]   [Full Text] [Related]  

  • 57. Exenatide-a potential role in treatment of HNF1-alpha MODY in obese patients?
    Ahluwalia R; Perkins K; Ewins D; Goenka N
    Diabet Med; 2009 Aug; 26(8):834-5. PubMed ID: 19709161
    [No Abstract]   [Full Text] [Related]  

  • 58. Preoperative considerations of new long-acting glucagon-like peptide-1 receptor agonists in diabetes mellitus.
    Hulst AH; Polderman JAW; Siegelaar SE; van Raalte DH; DeVries JH; Preckel B; Hermanides J
    Br J Anaesth; 2021 Mar; 126(3):567-571. PubMed ID: 33341227
    [No Abstract]   [Full Text] [Related]  

  • 59. Comparative studies of insulin vs glucagon-like peptide-1 receptor agonists in patients initiating injectable therapy.
    Dejgaard TF; Madsbad S
    Diabetes Obes Metab; 2017 Feb; 19(2):153-155. PubMed ID: 27735120
    [No Abstract]   [Full Text] [Related]  

  • 60. American diabetes association - 65th Scientific Sessions.
    Erlich R
    IDrugs; 2005 Aug; 8(8):605-7. PubMed ID: 16044360
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.